Mon, Sep 22, 2014, 2:25 AM EDT - U.S. Markets open in 7 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • whippersnapper65 whippersnapper65 Oct 4, 2013 11:29 PM Flag

    November 11 and 25

    November 11 will be the first trading day after Celldex releases its data from the phase 1b trial of CDX-1127. If CLDX does not close above $40 on November 8, it certainly will on November 11.

    November 25 will be the first trading day after Celldex releases its data from the ReACT trial of Rindopepimut. If CLDX does not close above $45 on November 22, it certainly will on November 25.

    Just think about that.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Are these specific dates on their site? Yes. of course November, but I thought the specific dates of release were more. vague.

      • 1 Reply to neshua10
      • The Society for Immunotherapy of Cancer meets from November 7-10. At that conference Celldex will present its CDX-1127 phase-1b data. It is unclear to me when or how Celldex will present that data. I cannot find specific program or session information.

        The Society for Neuro-Oncology meets from November 22-24. Celldex's presentation of data from its ReACT trial is slated for Sunday, November 24 from 10:20 - 12:00, as below.

        IT-018 ReACT: a phase II study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma -- David Reardon*1, Gordon Li2, Lawrence Recht2, Karen Fink3, Louis Nabors4, David Tran5, Annick Desjardins6, Nitin Chandramouli7, J. Paul Duic8, Morris Groves9, Anne Clarke10, Thomas Hawthorne10, Jennifer Green10, Michael Yellin10, John Sampson6
        1Dana-Farber Cancer Institute, USA, 2Stanford University School of Medicine, USA, 3Baylor Research Institute, USA, 4University of Alabama, USA, 5Washington University, USA, 6Duke University Medical Center, USA, 7Utah Cancer Specialists, USA, 8The Long Island Brain Tumor Center at Neurological Surgery, P.C, USA, 9Texas Oncology, USA, 10Celldex Therapeutics, Inc., USA

        Sentiment: Strong Buy

    • Data from trials will be very important. Long believes the data will be good. I look forward to CLDX going over $40 this year.

      Sentiment: Strong Buy

 
CLDX
14.05-0.04(-0.28%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.